What the New FDA Guidance on Hormone Therapy Means for You

Date: November 13, 2026
By: Justin Levesque, PharmD

If you’ve heard about a change to the FDA hormone therapy warning, here’s what that actually means, and what it doesn’t.

The Short Version

In late 2025, the FDA removed the strongest warning label – often called a “black box” warning, often from most menopausal hormone therapy products. That warning had linked hormone therapy to heart disease, breast cancer, and dementia. After reviewing the science, the FDA concluded that warning was based on outdated research and had, for over two decades, made many women afraid to try a treatment that could meaningfully help them.

This doesn’t mean hormone therapy is risk-free, and it doesn’t mean it’s right for everyone. It means the label is now more accurate, and the conversation between you and your provider can start from better information.

Why the Old FDA Hormone Therapy Warning Existed

The original warning came from a large study in the early 2000s. Later, researchers found a problem with how that study was designed: it grouped women in their 50s together with women in their 70s, even though menopause typically begins around age 50. When researchers looked more closely at women in their 50s specifically (the age when most people actually start hormone therapy), the benefits generally outweighed the risks.

In other words, the original warning wasn’t necessarily wrong for every woman studied, but it was applied far too broadly, and it scared off many women who likely would have benefited.

What Stayed the Same

One warning was not removed: for women who still have a uterus and take estrogen alone (without a second hormone called progestogen), there remains a risk of endometrial cancer. This is why women with a uterus are typically prescribed estrogen along with progestogen, as this combination protects the uterine lining. This part of the guidance hasn’t changed.

It’s also still true that hormone therapy isn’t automatically right for everyone. Your own health history matters, including things like a personal history of blood clots, stroke, heart attack, certain cancers, or liver disease. That’s a conversation to have directly with your prescriber.

What This Means for You

As manufacturers update their labels, you may see the revised FDA hormone therapy warning reflected in less alarming language on your prescription or package insert.

  • You may hear less alarming language when you pick up a prescription or read the package insert going forward, as manufacturers update their labels.
  • The evidence suggests hormone therapy is often most beneficial when started within about 10 years of menopause beginning, or before age 60. This is a good thing to ask your prescriber about if you’re considering starting therapy.
  • This is a good time to revisit the conversation with your prescriber if fear of the old warning previously kept you from considering hormone therapy for symptoms like hot flashes, night sweats, sleep trouble, or vaginal dryness.
  • Your individual risk factors still matter. This change reflects an update to general guidance. It’s not a signal that everyone should take hormone therapy, or that no risks exist.

Questions to Bring to Your Provider

  • Am I a good candidate for hormone therapy given my personal and family health history?
  • When should I start, if I’m going to?
  • What form makes sense for me: pill, patch, gel, or cream?
  • What’s my plan to protect against endometrial cancer risk? (Relevant if you still have a uterus.)
  • What symptoms or changes should prompt me to check back in?

Is This Actually Settled Science?

Not entirely, and it’s worth knowing that. The FDA’s decision is based on real research, including a large 2025 study that looked back at the original data with a closer focus on women’s age when they started treatment. But it’s not something every expert agrees on. Some researchers who worked on the original safety oversight for that early-2000s study have publicly pushed back, saying the FDA should have gone through a more thorough, independent review process before making this change.

That disagreement is mostly about process (how the decision was made) rather than a dispute that hormone therapy is dangerous for younger, recently menopausal women. But it’s a good reminder that this is genuinely evolving science, not a settled matter, and it’s part of why an individual conversation with your own provider matters more than any general label.

Bottom Line

The science on hormone therapy has evolved, and the FDA’s updated guidance reflects that. If concern about the old FDA hormone therapy warning has kept you on the sidelines, it may be worth a conversation with your provider to see whether hormone therapy is a good option for you now. If you’d like support preparing for that conversation, our pharmacists offer hormone consults in person or by telehealth, and we work alongside your prescriber. Book a call to find out more details.

Sources

This information is educational and does not replace advice from your prescriber or pharmacist. Talk to your healthcare provider about your specific situation before starting or stopping any medication.